Evidence map›Paper›PMID 42886232›Full record

ArticleBioprocess and biosystems engineering2026

Integrated dual carbon source and TCA intermediate supplementation in fed-batch fermentation of CHO cells for reduced lactate and ammonia accumulation and improved IgG1 monoclonal antibody titre.

Ashwin Naidu, Krutika Padhye, Prajakta Dandekar, Ratnesh Jain

Abstract read
PubMed Publisher
In one paragraph

Article in Bioprocess and biosystems engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ashwin NaiduDepartment of Biological Sciences and Biotechnology, Institute of Chemical Technology, Matunga, Mumbai, 400019, India.ORCID http://orcid.org/0009-0003-0178-9613
Krutika PadhyeDepartment of Biological Sciences and Biotechnology, Institute of Chemical Technology, Matunga, Mumbai, 400019, India.ORCID http://orcid.org/0009-0008-0049-8052
Prajakta DandekarDepartment of Pharmaceutical Science and Technology, Institute of Chemical Technology, Matunga, Mumbai, 400019, India.ORCID http://orcid.org/0000-0001-5968-1072
Ratnesh JainDepartment of Biological Sciences and Biotechnology, Institute of Chemical Technology, Matunga, Mumbai, 400019, India. rd.jain@ictmumbai.edu.in.ORCID https://orcid.org/0000-0001-6887-9400

Funding

Department of Science and Technology-Promotion of University Research and Scientific Excellence (DST-PURSE) DST-PURSE Program (2020; TPN-57255)
6 · The paper itself

Abstract

Chinese hamster ovary (CHO) cells are the workhorse of biopharmaceutical manufacturing, yet lactate and ammonia accumulation remain persistent bottlenecks that compromise cell viability, productivity, and product quality. To address this, we present an integrated feeding strategy systematically combining Ala-Gln, TCA intermediates, and glucose-galactose dual carbon feed evaluated head-to-head across four defined fed-batch conditions for CHO cultures producing an IgG1 monoclonal antibody (mAb). Conventional L-glutamine was replaced with L-alanyl-glutamine (Ala-Gln) to curb spontaneous ammonia release, while a customized "efficient feed mix" enriched with 2× TCA cycle intermediates and branched-chain amino acids combined with a glucose-galactose co-feed (2 mM glucose + 30 mM galactose) was introduced upon glucose depletion. Four fed-batch conditions were evaluated: a glutamine control (FB-01), Ala-Gln alone (FB-02), Ala-Gln with TCA intermediates (FB-03), and the complete integrated strategy (FB-04). FB-04 delivered an > 83% reduction in peak lactate (4.0 mM) and 80% reduction in ammonia (< 2.0 mM), sustained cell viability above 85% through day 11, and achieved a 93% higher mAb titre (1.72 g/L) with peak Viable count density (VCD) of 39 × 10⁶ cells/mL. Glycosylation profiles (19.0% galactosylation) remained aligned with innovator benchmarks. This study presents the first direct head-to-head benchmarking of Ala-Gln substitution, TCA intermediate supplementation, and galactose co-feeding in a single CHO fed-batch platform, demonstrating their combined metabolic and glycosylation benefits against a glutamine control.

Indexed as

Ala-GlnAmmonia reductionChinese hamster ovary cellsFed-batch fermentationLactate mitigationMetabolic optimizationMonoclonal antibodyTCA cycle intermediates

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.